Equity Overview
Price & Market Data
Price: $0.0175
Daily Change: +$0.0₃8 / 4.57%
Range: $0.0127 - $0.0187
Market Cap: $695,525
Volume: 430,476
Performance Metrics
1 Week: 29.87%
1 Month: 17.65%
3 Months: -28.57%
6 Months: -88.17%
1 Year: -96.67%
YTD: -87.97%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.